Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

Katharine A  Relph; Clark D Russell; Cameron Fairfield; Lance  Turtle; Thushan I. De Silva; Matthew K Siggins; Thomas  Drake; Ryan S  Thwaites; Simon Abrams; Shona C Moore; Hayley E Hardwick; Wilna Oosthuyzen; Ewen M Harrison; Annemarie B Docherty; Peter Jm Openshaw; J Kenneth Baillie; Malcolm G Semple; Antonia Ho

doi:10.1093/ofid/ofac179

Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

Katharine A Relph, Clark D Russell^*, Cameron Fairfield, Lance Turtle, Thushan I. De Silva, Matthew K Siggins, Thomas Drake, Ryan S Thwaites, Simon Abrams, Shona C Moore, Hayley E Hardwick, Wilna Oosthuyzen, Ewen M Harrison, Annemarie B Docherty, Peter Jm Openshaw, J Kenneth Baillie, Malcolm G Semple, Antonia Ho

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Admission procalcitonin measurements and microbiology results were available for 1040 hospitalised adults with COVID-19 (from 48,902 included in the ISARIC/WHO CCP-UK study). Although procalcitonin was higher in bacterial co-infection, this was neither clinically significant (0.33 ng/mL [IQR 0.11-1.70] vs. 0.24 [0.10-0.90]) nor diagnostically useful (ROC AUC 0.56, 95% CI 0.51-0.60).

Original language	English
Article number	ofac179
Journal	Open forum infectious diseases
Volume	9
Issue number	5
Early online date	1 May 2022
DOIs	https://doi.org/10.1093/ofid/ofac179
Publication status	Published - 2 May 2022

Keywords / Materials (for Non-textual outputs)

COVID-19
SARS-CoV-2
procalcitonin
coinfection

Access to Document

10.1093/ofid/ofac179Licence: Creative Commons: Attribution (CC-BY)

manuscript_cleanAccepted author manuscript, 78.3 KBLicence: Creative Commons: Attribution (CC-BY)
ofac179Final published version, 494 KBLicence: Creative Commons: Attribution (CC-BY)

Cite this

Relph, K. A., Russell, C. D., Fairfield, C., Turtle, L., De Silva, T. I., Siggins, M. K., Drake, T., Thwaites, R. S., Abrams, S., Moore, S. C., Hardwick, H. E., Oosthuyzen, W., Harrison, E. M., Docherty, A. B., Openshaw, P. J., Baillie, J. K., Semple, M. G., & Ho, A. (2022). Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission. Open forum infectious diseases, 9(5), Article ofac179. https://doi.org/10.1093/ofid/ofac179

@article{9e2415dc7d6e4d0a90402426fc472586,

title = "Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission",

abstract = "Admission procalcitonin measurements and microbiology results were available for 1040 hospitalised adults with COVID-19 (from 48,902 included in the ISARIC/WHO CCP-UK study). Although procalcitonin was higher in bacterial co-infection, this was neither clinically significant (0.33 ng/mL [IQR 0.11-1.70] vs. 0.24 [0.10-0.90]) nor diagnostically useful (ROC AUC 0.56, 95% CI 0.51-0.60).",

keywords = "COVID-19, SARS-CoV-2, procalcitonin, coinfection",

author = "Relph, {Katharine A} and Russell, {Clark D} and Cameron Fairfield and Lance Turtle and {De Silva}, {Thushan I.} and Siggins, {Matthew K} and Thomas Drake and Thwaites, {Ryan S} and Simon Abrams and Moore, {Shona C} and Hardwick, {Hayley E} and Wilna Oosthuyzen and Harrison, {Ewen M} and Docherty, {Annemarie B} and Openshaw, {Peter Jm} and Baillie, {J Kenneth} and Semple, {Malcolm G} and Antonia Ho",

note = "Funding Information: This work was supported by the National Institute for Health Research (NIHR) (grant number CO-CIN-01) Publisher Copyright: {\textcopyright} 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2022",

month = may,

day = "2",

doi = "10.1093/ofid/ofac179",

language = "English",

volume = "9",

journal = "Open forum infectious diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "5",

}

Relph, KA, Russell, CD, Fairfield, C, Turtle, L, De Silva, TI, Siggins, MK, Drake, T, Thwaites, RS, Abrams, S, Moore, SC, Hardwick, HE, Oosthuyzen, W, Harrison, EM , Docherty, AB, Openshaw, PJ, Baillie, JK, Semple, MG & Ho, A 2022, 'Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission', Open forum infectious diseases, vol. 9, no. 5, ofac179. https://doi.org/10.1093/ofid/ofac179

Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission. / Relph, Katharine A ; Russell, Clark D; Fairfield, Cameron et al.
In: Open forum infectious diseases, Vol. 9, No. 5, ofac179, 02.05.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

AU - Relph, Katharine A

AU - Russell, Clark D

AU - Fairfield, Cameron

AU - Turtle, Lance

AU - De Silva, Thushan I.

AU - Siggins, Matthew K

AU - Drake, Thomas

AU - Thwaites, Ryan S

AU - Abrams, Simon

AU - Moore, Shona C

AU - Hardwick, Hayley E

AU - Oosthuyzen, Wilna

AU - Harrison, Ewen M

AU - Docherty, Annemarie B

AU - Openshaw, Peter Jm

AU - Baillie, J Kenneth

AU - Semple, Malcolm G

AU - Ho, Antonia

N1 - Funding Information: This work was supported by the National Institute for Health Research (NIHR) (grant number CO-CIN-01) Publisher Copyright: © 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2022/5/2

Y1 - 2022/5/2

N2 - Admission procalcitonin measurements and microbiology results were available for 1040 hospitalised adults with COVID-19 (from 48,902 included in the ISARIC/WHO CCP-UK study). Although procalcitonin was higher in bacterial co-infection, this was neither clinically significant (0.33 ng/mL [IQR 0.11-1.70] vs. 0.24 [0.10-0.90]) nor diagnostically useful (ROC AUC 0.56, 95% CI 0.51-0.60).

AB - Admission procalcitonin measurements and microbiology results were available for 1040 hospitalised adults with COVID-19 (from 48,902 included in the ISARIC/WHO CCP-UK study). Although procalcitonin was higher in bacterial co-infection, this was neither clinically significant (0.33 ng/mL [IQR 0.11-1.70] vs. 0.24 [0.10-0.90]) nor diagnostically useful (ROC AUC 0.56, 95% CI 0.51-0.60).

KW - COVID-19

KW - SARS-CoV-2

KW - procalcitonin

KW - coinfection

U2 - 10.1093/ofid/ofac179

DO - 10.1093/ofid/ofac179

M3 - Article

SN - 2328-8957

VL - 9

JO - Open forum infectious diseases

JF - Open forum infectious diseases

IS - 5

M1 - ofac179

ER -

Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Other files and links

Fingerprint

Cite this